All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @biamotao on TikTok ยท 9s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @biamotao's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00One, two, three.

@biamotao's Mounjaro weight loss claims, fact-checked

๐‘ฃฒ Bia Mota ๐œ—เงŽ

TikTok creator

157.3K viewsWatch on TikTok โ†’

Quick answer

Tirzepatide (Mounjaro) is a dual GLP-1/GIP receptor agonist that showed 15-21% average weight loss over 72 weeks in the SURMOUNT-1 trial. It works by slowing gastric emptying and reducing appetite through multiple hormone pathways.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded TirzepatideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Tirzepatide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @biamotao's Mounjaro weight loss claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

Compounded Tirzepatide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Claim path

Keep researching this tirzepatide video claims cluster

Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@biamotao's Mounjaro weight loss claims, fact-checked" from ๐‘ฃฒ Bia Mota ๐œ—เงŽ. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Tirzepatide (Mounjaro) is a dual GLP-1/GIP receptor agonist that showed 15-21% average weight loss over 72 weeks in the SURMOUNT-1 trial.

The reason this review is not generic is the source wording and the canonical claim label "glp1 2 meses de mounjaro menos 9 kg tenho muito para eliminar a." In this clip, the useful excerpt is: "One, two, three." That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Her 9kg loss in 8 weeks represents faster than typical results, though within possible range
People who land here are usually trying to understand whether the Compounded Tirzepatide claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' Compounded Tirzepatide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Tirzepatide (Mounjaro) is a dual GLP-1/GIP receptor agonist that showed 15-21% average weight loss over 72 weeks in the SURMOUNT-1 trial.

FormBlends verdict

Compounded Tirzepatide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Tirzepatide (Mounjaro) is a dual GLP-1/GIP receptor agonist that showed 15-21% average weight loss over 72 weeks in the SURMOUNT-1 trial. It works by slowing gastric emptying and reducing appetite through multiple hormone pathways.
  • SURMOUNT-1 trial showed tirzepatide users lost 15-21% body weight on average over 72 weeks
  • Her 9kg loss in 8 weeks represents faster than typical results, though within possible range

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.

Review Compounded Tirzepatide

What You'll Learn

  • SURMOUNT-1 trial showed tirzepatide users lost 15-21% body weight on average over 72 weeks
  • Her 9kg loss in 8 weeks represents faster than typical results, though within possible range
  • 81% of trial participants experienced nausea as a side effect
  • Mounjaro costs $900-1,200 monthly without insurance coverage
  • Individual results vary significantly even with identical doses and timelines
  • Clinical trials require medical supervision that casual social media posts lack
  • Tirzepatide outperformed semaglutide in direct comparison studies

Our take ยท Written by FormBlends editorial team ยท Reviewed by FormBlends Medical Team ยท This is not a transcript. It is our independent review of the video above.

What does this TikToker actually claim?

@biamotao says she lost 9 kilograms (about 20 pounds) in two months on Mounjaro and plans to continue losing weight. That's it.

The post is refreshingly straightforward compared to most weight loss TikToks. No dramatic before-and-after photos, no miracle claims, just a basic progress report. She acknowledges having "much more to eliminate," suggesting she's early in her weight loss journey.

At 157,000 views, this simple update resonated with people following similar paths. But does her timeline match what clinical trials show?

Does her weight loss timeline check out?

Her reported loss of 9kg in 8 weeks translates to roughly 1.1kg per week, which falls within expected ranges for tirzepatide (Mounjaro's active ingredient).

The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) found participants on 15mg tirzepatide lost an average of 6.2kg by week 12. However, weight loss isn't linear. Most people see faster initial drops due to water weight and appetite suppression.

Her timeline is plausible but represents the higher end of typical results. The same trial showed some participants lost significantly more in early weeks, while others took longer to see substantial changes.

What does the science say about Mounjaro's effectiveness?

Tirzepatide consistently outperforms other GLP-1 medications in head-to-head comparisons. The SURMOUNT-1 trial enrolled 2,539 adults with obesity and found average weight losses of 15%, 19.5%, and 20.9% at 5mg, 10mg, and 15mg doses respectively over 72 weeks.

That's substantially better than semaglutide's 14.9% average in STEP 1 (Wilding et al., NEJM, 2021). Tirzepatide targets both GLP-1 and GIP receptors, which may explain its superior performance.

Real-world data from insurance claims analysis shows similar patterns, though slightly lower average losses than clinical trials.

What context is missing from her post?

@biamotao doesn't mention side effects, which affect most people starting tirzepatide. In SURMOUNT-1, 81% experienced nausea, 51% had diarrhea, and 48% reported vomiting.

She also skips the medication's cost considerations. Mounjaro typically costs $900-1,200 monthly without insurance coverage, making it inaccessible for many people who could benefit.

The post lacks information about lifestyle changes she may have made alongside the medication. While tirzepatide works independently of diet changes, most successful users combine it with modified eating patterns.

Should you trust TikTok weight loss updates?

Individual results like @biamotao's can't predict your experience, even with the same medication. Clinical trials show enormous variation between participants.

Her honest, low-key approach is actually more trustworthy than dramatic transformation posts flooding social media. She doesn't promise miraculous results or sell anything.

Still, social media posts shouldn't influence medical decisions. The SURMOUNT trials required extensive screening and monitoring that casual TikTok updates obviously lack. Talk to a healthcare provider about whether tirzepatide makes sense for your situation.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

๐‘ฃฒ Bia Mota ๐œ—เงŽ ยท TikTok creator

157.3K views on this video

2 meses de mounjaro, menos 9 kg, tenho muito para eliminar ainda ๐Ÿ’‹

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about surmount-1 trial showed tirzepatide users lost 15-21% body weight on?

SURMOUNT-1 trial showed tirzepatide users lost 15-21% body weight on average over 72 weeks

What does the video say about her 9kg loss in 8 weeks represents faster than typical?

Her 9kg loss in 8 weeks represents faster than typical results, though within possible range

What does the video say about 81% of trial participants experienced nausea as a side effect?

81% of trial participants experienced nausea as a side effect

What does the video say about mounjaro costs $900-1,200 monthly without insurance coverage?

Mounjaro costs $900-1,200 monthly without insurance coverage

What does the video say about individual results vary significantly even with identical doses?

Individual results vary significantly even with identical doses and timelines

What does the video say about clinical trials require medical supervision?

Clinical trials require medical supervision that casual social media posts lack

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by ๐‘ฃฒ Bia Mota ๐œ—เงŽ, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.